Research article
Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer
-
* Corresponding author: Hee J Chang heejincmd@yahoo.com
- † Equal contributors
BMC Cancer 2009, 9:246 doi:10.1186/1471-2407-9-246
No comments have yet been made on this article.